PATENT CLAIM ANALYSIS

Application Number: 15870308
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "04400A"]

Abstract:
The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Claim (Index 1):
An antisense oligomer which causes skipping of the 55th exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to any one of the nucleotide sequences consisting of the 10th to the 31st, the 10th to the 32nd, the 11th to the 31st, the 11th to the 32nd, the 13th to the 34th, the 13th to the 35th, the 13th to the 36th, 14th to the 35th, the 14th to the 36th, the 15th to the 35th, the 15th to the 36th, the 16th to the 34th, the 16th to the 35th, and the 16th to the 36th nucleotides, from the 5\u2032 end of the 55th exon in the human dystrophin gene.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 86.0
- Lexical Diversity: 1.75758
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14368307', '15339069', '13819520', '15619996', '14615504']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.9113435050445228
- 35 USC 102 Novelty (BERT): 0.6976794973312417
- Combined Prediction Score: 0.8899771042731945
- Mean Citation Score: 750.7423379999999
- Max Citation Score: 937.6796
- Similarity Product: 711.0025970590116

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test